CAJ | 학술논문

目的：观察吸入激素联合缓释茶碱对中度持续哮喘患者的治疗作用。方法：中度哮喘患者60例，随机分为试验组30例和对照组30例。试验组患者每日吸入普米克都保，每吸200μg，每日2次；口服多索茶碱片0．2每日2次。对照组患者每日吸入布地奈德／福莫特罗每吸160／4．5μg，每日2吸。疗程3个月。比较治疗前后FeNO、痰嗜酸粒细胞计数、PEF、ACT评分等指标的变化，并与对照组相比较，评估该方案的临床使用价值。结果：治疗1个月时，试验组在改善PEF、ACT评分方面，明显不及对照组（均P＜0．05），痰嗜酸粒细胞比例的改善优于对照组（P＜0．05），FeNO无明显区别（P＞0．05）；治疗3个月时，试验组对痰嗜酸粒细胞比例的改善优于对照组（P＜0．05），对FeNO、PEF、ACT评分的改善与对照组无明显区别（均P＞0．05）。结论：布地奈德／多索茶碱与布地奈德／福莫特罗控制哮喘的效果无明显区别。
목적：관찰흡입격소연합완석다감대중도지속효천환자적치료작용。방법：중도효천환자60례，수궤분위시험조30례화대조조30례。시험조환자매일흡입보미극도보，매흡200μg，매일2차；구복다색다감편0．2매일2차。대조조환자매일흡입포지내덕／복막특라매흡160／4．5μg，매일2흡。료정3개월。비교치료전후FeNO、담기산립세포계수、PEF、ACT평분등지표적변화，병여대조조상비교，평고해방안적림상사용개치。결과：치료1개월시，시험조재개선PEF、ACT평분방면，명현불급대조조（균P＜0．05），담기산립세포비례적개선우우대조조（P＜0．05），FeNO무명현구별（P＞0．05）；치료3개월시，시험조대담기산립세포비례적개선우우대조조（P＜0．05），대FeNO、PEF、ACT평분적개선여대조조무명현구별（균P＞0．05）。결론：포지내덕／다색다감여포지내덕／복막특라공제효천적효과무명현구별。
Objective To observe the effect of budesonide/doxofylline on patients with persistent asthma. Methods Sixty patients with moderate asthma were randomly divided into treatment group and control group. Patients in treatment group accepted the inhalation budesonide 400μg/d and doxofylline tablet 0.2 bid po but those in control group accepted the inhalation budesonide/formoterol 160/4.5μg bid. FeNO, sputum eosinophils, PEF and ACT scores were compared between two groups. Results PEF and ACT scores in treatment group were lower to those in control group (P<0.05), whereas the score of sputum eosinophils in treatment group was higher (P<0.05) one month later. There was no significant difference in FeNO between two groups (P>0.05). After three months, sputum eosinophils in treatment group were better than that in control group (P<0.05), whereas there was no significant difference in PEF, ACT scores and FeNO between two groups(P>0.05). Conclusion There is no significant difference in controlling asthma between budesonide/doxofylline and budesonide/formooterol